TABLE 2.
Therapeutic activities of MAbs against RtxA1-Ca
| Control or antibody | % of surviving mice (no. of survivors/total)b | P value | Antibody sourcec |
|---|---|---|---|
| PBS control | 30 (16/53) | ||
| Antibodies | |||
| 13RA | 20 (2/10) | 0.5962 | ASC |
| 21RA | 100 (10/10) | 0.0001 | PUR (0.5 mg) |
| 24RA | 90 (9/10) | 0.0008 | PUR (1 mg) |
| 45RA | 30 (3/10) | 0.6078 | PUR (1 mg) |
| 47RA | 90 (9/10) | 0.0008 | PUR (1 mg) |
| 50RA | 40 (4/10) | 0.5675 | ASC |
a
To determine the therapeutic efficacies of the MAbs, 8-week-old CD1 mice were challenged intraperitoneally (i.p.) with 1 × 106 CFU of V. vulnificus strain M06-24/O. Then, a single dose of purified MAbs (0.5 mg or 1 mg) or ascitic fluid (200 μl) was passively transferred i.p. 1 h postinfection. Mice were followed for 96 h. P values were determined by comparison to the PBS-treated control group.
b
Numbers in parentheses represent the number of survivors and the total number of infected mice.
c
Values in parentheses indicate the amount of MAb administered to each mouse. ASC, ascitic fluid; PUR, purified antibody.